CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Pfizer Inc.

Tara Moroz, PhD, Sr. Director, Global Medical Communications and Content - Specialty Care, Rare Disease

Gene Therapy Clearly Communicated: The Importance of Patient-Centricity, An Omnichannel Approach, and Health Literacy

Tara Moroz

Tara Moroz, PhD

Medical Communications Director

New medicines which have the potential to transform patients’ lives need to be offered to the appropriate patient at the right time; this is important for most medicines but is especially so in the field of gene therapy. Clinicians need to know that new medicines are available and be able to describe potential risks & benefits to patients. Patients need to understand their options and be able to communicate treatment preferences back to the clinician. Although the concept of shared decision-making between healthcare professionals and patients is simple, fewer than 15% of US adults have the health literacy skills needed to engage with & navigate the health care system. Low levels of health literacy have also been reported across Europe and Asia.


Health literacy is described as the ability of a patient to read, understand, and use health information. Low health literacy can affect anyone, regardless of race, age, income, or educational level. It differs from fundamental literacy or basic literacy skills but is the cornerstone for shared decision-making. Health literacy allows patients to be active participants in their healthcare.


Broad efforts are underway by the Agency for Healthcare Research and Quality and the Institute for Healthcare Advancement, amongst others, to educate healthcare professionals on best practices in health literate patient communication, and to support organizations, such as hospitals, as producers of health information and services to equitably address health literacy. The adoption of best practices by healthcare professionals and organizations is increasing, but wide gaps exist, especially for new and scientifically complex innovations. In the absence of clearly communicated science there is room for misinformation, particularly in gene therapy where accusations of meddling with genetic makeup have the potential to run rife. Health misinformation has been connected to adverse consequences such as reduced quality of life, treatment delays, and increased risk of early mortality.


"Broad efforts are underway by the Agency for Healthcare Research and Quality and the Institute for Healthcare Advancement, to educate healthcare professionals on best practices in health literate patient communication, and to support organizations, such as hospitals, as producers of health information and services to equitably address health literacy."


How can a topic as complex as gene therapy be clearly communicated to allow for equitable and empowered decision-making? First, patients need to be engaged in gene therapy discovery, development, and delivery. For example, they can share the relevance of gene therapy (discovery phase), help select clinical trial endpoints that are important to them (development phase), and identify potential challenges and solutions to receiving gene therapy in the real world (delivery phase). Among other benefits, involvement of patients early and often can help shape a common lexicon for all stakeholders who contribute to bringing new therapies from bench to bedside, from scientists and healthcare professionals to payors and patients.


Second, healthcare stakeholders need timely and relevant gene therapy education. To achieve this goal healthcare education should consistently apply adult learning principles and provide tailored education to meet the needs of the learner. For example, gene therapy education needs for a rurally located family physician who needs to be able to identify patients who may be eligible for gene therapy, will be different from a specialist physician responsible for communicating the risk-benefit profile of a gene therapy with a specific patient, and different again from a payor who is assessing the value of a gene therapy. Medical education needs to evolve from its current conventional multichannel approach (lectures, articles, videos, webinars, podcasts, congresses, and social media) to an omnichannel approach.


An omnichannel approach delivers multichannel education in an integrated way. It is designed to spur greater engagement and learner retention by creating personalized learning experiences based on the learner’s needs and preferences. It additionally lends itself to continuous learning and bite-sized updates which may be especially important in areas of quickly evolving and complex science such as gene therapy. The healthcare industry can learn from omnichannel pioneers, such as Amazon and Spotify, as it transforms medical education to better meet the learning experience being demanded by healthcare stakeholders.


Third, patient materials should be developed following health literacy best practices for readability, understandability, and actionability, and at a minimum be routinely tested via freely available standardized tools such as the Flesch–Kincaid readability tests and the Patient Education Materials Assessment Tool.


None of these strategies to clearly communicate health information are unique to gene therapy. As the science becomes more complex, however, clear communication is imperative to ensure science, not health misinformation or an absence of information, leads the conversation.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Enterprise leaders must recognize that medical communications has evolved into a critical interface between scientific development and real-world adoption. This perspective underlines how precision in scientific storytelling now directly influences trust, treatment uptake and cross-functional alignment in complex therapeutic areas.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Abivax [EPA: ABVX]

    Leveraging Technological Advancements for Developing Innovative Therapeutics

    Marc de Garidel, CEO and Interim Chairman, Abivax

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review . All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/tara-moroz-nwid-3028.html